SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 28, 2018--
Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company
developing oral recombinant vaccines that are administered by tablet
rather than by injection, today announced that Sean Tucker, Ph.D., chief
scientific officer, will present summary data from the Phase 2 Challenge
Study of its H1 influenza oral tablet vaccine at the World Vaccine and
Immunotherapy Congress West Coast 2018, taking place from November
28-30, 2018 in San Diego, California.
Details of the presentation are as follows:
The Phase 2 study was completed with support from Biomedical Advanced
Research and Development Authority (BARDA). Vaxart received a $13.9
million contract from BARDA in September 2015 to support the advanced
development of more effective influenza vaccines to ultimately improve
seasonal and pandemic influenza preparedness. The contract was increased
to $15.7 million in 2017.
The project has been funded in whole or in part with federal funds from
the Department of Health and Human Services’ Office of the Assistant
Secretary for Preparedness and Response; Biomedical Advanced Research
and Development Authority under Contract No. HHSO100201500034C.
Vaxart is a clinical-stage biotechnology company focused on developing
oral recombinant protein vaccines based on its proprietary oral vaccine
platform. Vaxart’s vaccines are designed to generate broad and durable
immune responses that protect against a wide range of infectious
diseases and may also be useful for the treatment of chronic viral
infections and cancer. Vaxart’s vaccines are administered using a
convenient room temperature-stable tablet, rather than by injection.
Vaxart believes that tablet vaccines are easier to distribute and
administer than injectable vaccines, and have the potential to
significantly increase vaccination rates. Vaxart’s development programs
include oral tablet vaccines that are designed to protect against
norovirus, seasonal influenza and respiratory syncytial virus (RSV), as
well as a therapeutic vaccine for human papillomavirus (HPV). For more
information, please visit www.vaxart.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve
substantial risks and uncertainties. All statements, other than
statements of historical facts, included in this press release regarding
our strategy, prospects, plans and objectives, results from preclinical
and clinical trials, commercialization agreements and licenses, beliefs
and expectations of management are forward-looking statements. These
forward-looking statements may be accompanied by such words as
“believe,” “could,” “potential”, “will” and other words and terms of
similar meaning. Examples of such statements include, but are not
limited to, statements relating to the Vaxart’s ability to develop and
commercialize its product candidates and clinical results and trial
data; and the potential of its product candidates to significantly
increase vaccination rates. Vaxart may not actually achieve the plans,
carry out the intentions or meet the expectations or projections
disclosed in our forward-looking statements and you should not place
undue reliance on these forward-looking statements. Actual results or
events could differ materially from the plans, intentions, expectations
and projections disclosed in the forward-looking statements. Various
important factors could cause actual results or events to differ
materially from the forward-looking statements that Vaxart makes, that
Vaxart’s product candidates may not be approved by the FDA or non-U.S.
regulatory authorities; that, even if approved by the FDA or non-U.S.
regulatory authorities, Vaxart’s product candidates may not achieve
broad market acceptance; that Vaxart may experience manufacturing issues
and delays; and other risks described in the “Risk Factors” sections of
Vaxart’s Quarterly Reports filed on Form 10-Q and of Vaxart’s other
periodic reports filed with the SEC. Vaxart does not assume any
obligation to update any forward-looking statements, except as required
View source version on businesswire.com: https://www.businesswire.com/news/home/20181128005175/en/
Source: Vaxart, Inc.
Stern Investor Relations